# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001437749-17-010129
Filing Date
2017-05-26
Accepted
2017-05-26 09:01:07
Documents
4
Period of Report
2017-07-07
Effectiveness Date
2017-05-26

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | FORM DEF 14A | atrn20170518_def14a.htm | DEF 14A | 525443
2 |  | card3.jpg | GRAPHIC | 103692
3 |  | card2.jpg | GRAPHIC | 371635
4 |  | card1.jpg | GRAPHIC | 192010
| Complete submission text file | 0001437749-17-010129.txt |  | 1445911

Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-51353 | Film No.: 17871902
SIC: 7389 Services-Business Services, NEC